High-Iron Consumption Impairs Growth and Causes Copper-Deficiency Anemia in Weanling Sprague-Dawley Rats

Jung-Heun Ha, Caglar Doguer, Xiaoyu Wang, Shireen R. Flores, James F. Collins*

Food Science and Human Nutrition Department, University of Florida, Gainesville, Florida, United States of America

* jfcollins@ufl.edu

Abstract

Iron-copper interactions were described decades ago; however, molecular mechanisms linking the two essential minerals remain largely undefined. Investigations in humans and other mammals noted that copper levels increase in the intestinal mucosa, liver and blood during iron deficiency, tissues all important for iron homeostasis. The current study was undertaken to test the hypothesis that dietary copper influences iron homeostasis during iron deficiency and iron overload. We thus fed weanling, male Sprague-Dawley rats (n = 6-11/group) AIN-93G-based diets containing high (~8800 ppm), adequate (~80) or low (~11) iron in combination with high (~183), adequate (~8) or low (~0.9) copper for 5 weeks. Subsequently, the iron- and copper-related phenotype of the rats was assessed. Rats fed the low-iron diets grew slower than controls, with changes in dietary copper not further influencing growth. Unexpectedly, however, high-iron (HFe) feeding also impaired growth. Furthermore, consumption of the HFe diet caused cardiac hypertrophy, anemia, low serum and tissue copper levels and decreased circulating ceruloplasmin activity. Intriguingly, these physiologic perturbations were prevented by adding extra copper to the HFe diet. Furthermore, higher copper levels in the HFe diet increased serum nonheme iron concentration and transferrin saturation, exacerbated hepatic nonheme iron loading and attenuated splenic nonheme iron accumulation. Moreover, serum erythropoietin levels, and splenic erythroferrone and hepatic hepcidin mRNA levels were altered by the dietary treatments in unanticipated ways, providing insight into how iron and copper influence expression of these hormones. We conclude that high-iron feeding of weanling rats causes systemic copper deficiency, and further, that copper influences the iron-overload phenotype.

Introduction

Iron is an essential trace element that is required for oxygen transport and storage, energy metabolism, antioxidant function and DNA synthesis. Abnormal iron status, as seen in iron deficiency and iron overload, perturbs normal physiology. Copper is also an essential nutrient for humans, being involved in energy production, connective tissue formation and
neurotransmission. Copper, like iron, is required for normal erythropoiesis; copper deficiency causes an iron-deficiency-like anemia [1]. Moreover, copper homeostasis is closely linked with iron metabolism, since iron and copper have similar physiochemical and toxicological properties. Physiologically-relevant iron-copper interactions were first described in the mid-1800s, when chlorosis or the “greening sickness” was abundant in young women of industrial Europe [2]. Although specific clinical information is lacking, chlorosis likely resulted from iron-deficiency anemia (IDA) [1], a condition which was, and still is, common in this demographic group. Women who worked in copper factories were, however, protected from chlorosis [2], suggesting that copper positively influences iron homeostasis [1].

Iron-copper interactions in biological systems may be attributed to their positive charges, similar atomic radii, and common metabolic fates. For example, dietary iron and copper are both absorbed in the proximal small intestine [1]. Also, iron and copper must be reduced before uptake into enterocytes and further, both metals are oxidized after (or concurrent with) export into the interstitial fluids (enzymatic iron oxidation may occur while copper oxidation is likely spontaneous). Moreover, both metals are involved in redox chemistry in which they function as enzyme cofactors, and both can be toxic when in excess. Furthermore, a reciprocal relationship between iron and copper has been established in some tissues. For example, copper accumulates in the liver during iron deficiency, and iron accumulates during copper deficiency [1, 2]. Copper levels also increase in the intestinal mucosa and blood during iron deprivation [2, 3]. Despite these intriguing past observations, the molecular bases of physiologically-relevant iron-copper interactions are yet to be elucidated in detail. The aim of this investigation was thus to provide additional, novel insight into the interplay between iron and copper.

We have been investigating how copper influences intestinal iron absorption during iron deficiency for the past decade. It was noted that an enterocyte copper transporter, copper-transporting ATPase 1 (Atp7a), was strongly induced during iron deficiency in rats [3, 4] and mice [5]. Additional experimentation demonstrated that the mechanism of Atp7a induction was via a hypoxia-inducible transcription factor (Hif2α) [6, 7]. Importantly, this transcriptional mechanism is also invoked to increase expression of the intestinal iron importer (divalent metal-ion transporter 1 [Dmt1]), a brush-border membrane (BBM) ferrireductase (duodenal cytochrome b [Dcytb]), and the basolateral membrane (BLM) iron exporter (ferroportin 1 [Fpn1]). Moreover, it was suggested that the principle intestinal iron importer, Dmt1, could transport copper during iron deficiency [8]. In the current investigation, we sought to broaden our experimental approach by testing the hypothesis that dietary copper will influence iron metabolism during iron deficiency and iron overload (both being conditions that cause significant homeostatic perturbations in humans). The study design was to feed male, weanling, Sprague-Dawley rats one of 9 different diets, varying only in iron and copper content (low, adequate or high), for 5 weeks. After the dietary treatments, iron- and copper-related phenotypical parameters were analyzed to assess the impact of variable copper levels on iron homeostasis.

**Materials and Methods**

**Animal Experiments**

All animal studies were approved by the University of Florida IACUC. Three-week-old, male Sprague-Dawley rats (Harlan; Indianapolis, IN) were housed in stainless steel overhanging, wire mesh-bottom cages for 5 weeks until sacrifice. The 5 week time period was selected based upon our prior experience working with SD rats and related to the time point when significant iron deficiency has been noted (as reported in our previously published studies [3, 4, 9, 10]).
The rats had *ad libitum* access to food and purified water. Diets were fabricated based on the AIN-93G formulation [11, 12] (Dyets Inc.; Bethlehem, PA) and contained high (HFe), adequate (ADFe) or low (LFe) iron in combination with high (HCu), adequate (AdCu) or low (LCu) copper (Tables 1–3). We increased the amount of iron in the AdFe diet (from 50 ppm to 80) to ensure normal growth of these weanling rats. The HFe diets were modeled after published studies [13, 14]. The HCu diets contained ~20 times more copper than the adequate level. The rationale for this was that we anticipated that this amount of dietary copper would increase copper absorption yet be well below a toxic amount. Moreover, all diets contained extra sucrose (100 g/kg), as high carbonyl iron diets are otherwise unpalatable. All LFe and AdFe diets were isocaloric (3760 kcal/kg); however, the HFe diets contained slightly less energy (3724 kcal/kg; <1% less) since 10 g/kg of carbonyl iron was added (in place of a small amount of corn starch). Furthermore, animals were weighed weekly and food consumption was estimated by weighing the amount of food provided daily to each cage of rats. Animals were sacrificed by thoracotomy after CO2 narcosis.

### Determination of Iron and Copper Status

Hemoglobin (Hb) and hematocrit (Hct) levels were determined as described previously [5], using standard protocols. Liver samples were digested in acid solution (3 mol/L HCl, 10% trichloroacetic acid) and nonheme iron levels were determined, as previously described [15].

| Table 1. Iron and Copper Concentrations in Experimental Diets. |
|-------------------|-------------------|
| Diet              | Fe (ppm) | Cu (ppm) |
| LFe/LCu*          | 12.0     | 0.83     |
| LFe/AdCu          | 8.84     | 6.65     |
| LFe/HCu           | 12.4     | 182      |
| AdFe/LCu          | 93.7     | 0.92     |
| AdFe/AdCu         | 71.9     | 8.96     |
| AdFe/HCu          | 71.8     | 183      |
| HFe/LCu           | 90.36    | 0.94     |
| HFe/AdCu          | 8707     | 9.18     |
| HFe/HCu           | 8718     | 184      |

* H, high; Ad, adequate; L, low

* Determined by ICP/MS

| Table 2. Constant Ingredients in the 9 Experimental Diets. |
|-------------------|-------------------|
| Ingredient        | Amount (g/kg) |
| Casein            | 200             |
| Sucrose           | 100             |
| Soybean oil       | 70              |
| t-Butyhydroquinone| 0.014           |
| Dyetose           | 132             |
| Cellulose (micro) | 50              |
| Mineral Mix       | 35              |
| Vitamin Mix       | 10              |
| Choline Bitartrate| 2.5             |
| L-Cystine         | 3               |

* doi:10.1371/journal.pone.0161033.t001

* doi:10.1371/journal.pone.0161033.t002
Serum nonheme iron levels were quantified using a common colorimetric method [16]. For measurement of total iron-binding capacity (TIBC), a previously described colorimetric method was used [17, 18]. Transferrin (Tf) saturation was subsequently calculated as: serum iron/ TIBC x 100. Serum erythropoietin (Epo) levels were determined by ELISA (cat # LS-F10511; LifeSpan BioSciences Inc.; Seattle, WA). To assess serum ceruloplasmin (Cp) activity, a pd assay, which measures the amine oxidase activity of Cp, was performed according to a previously reported method [19, 20].

qRT-PCR

Total cellular RNA was isolated with RNAzol® RT reagent (Molecular Research Center Inc.; Cincinnati, OH) as previously described [21]. SYBR-Green qRT-PCR was performed according to a well-established protocol [9]. Oligonucleotide primers (Table 4) spanned large introns to avoid amplification from genomic DNA. Standard-curve reactions validated each primer pair, and melt curves routinely showed single amplicons. Expression of experimental genes was normalized to expression of cyclophilin (which did not significantly vary between groups).

Statistical Analysis

The homogeneity of variances was determined by the Fligner-Killeen test. If there was not homogeneity of variance in the data set, then data were transformed as a log10 scale prior to performing the statistical analyses. All statistical analyses were thus performed on data with equal variances. All results are expressed as means ± SDs or Box-and-Whisker plots except correlation data. Fligner-Killeen tests were performed in R (version 3.3.2) and the remaining analyses were performed using GraphPad (version 6.0.4 for Windows). The trends in data were analyzed using a 2-factor ANOVA test. If this analysis showed significant iron X copper interactions (p<0.05), Tukey’s multiple comparisons post hoc test was utilized to identify groups which varied significantly for a given parameter. A summary of all statistical comparisons is provided in Table 5 (iron main effect, copper main effect and iron X copper interactions); select

Table 3. Variable Ingredients in the 9 Experimental Diets.

| Ingredient | LFe/LCu | LFe/AdCu | LFe/HCu | AdFe/LCu | AdFe/AdCu | AdFe/HCu | HFe/LCu | HFe/AdCu | HFe/HCu |
|------------|---------|----------|---------|----------|-----------|----------|--------|----------|--------|
| Cornstarch (g/kg) | 397.486 | 397.486 | 397.486 | 397.486 | 397.486 | 397.486 | 397.486 | 397.486 | 397.486 |
| Fe Premix (10 mg/g) | 1 | 1 | 1 | 8 | 8 | 8 | - | - | - |
| Carbonyl Fe (g/kg) | - | - | - | - | - | - | 10 | 10 | 10 |
| Cu Premix (1 mg/g) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | - | - | - |
| Cu Premix (5 mg/g) | - | 1.6 | 1.6 | 40 | 40 | 40 | - | 1.6 | 40 |
| kcal/kg | 3760 | 3760 | 3760 | 3760 | 3760 | 3760 | 3724 | 3724 | 3724 |

do:10.1371/journal.pone.0161033.t003

Table 4. qRT-PCR Primer Sequences.

| Primer | Forward | Reverse |
|--------|---------|---------|
| Cyclophilin | 5’ -CTTGTGTCAATGGTCAACC-3’ | 5’ -TTGCTGTATTTGGAAACCTTCATTCGTCG-3’ |
| Bmp6 | 5’ -CTTAACAGAACAGCCCTTCATG-3’ | 5’ -AGCCTTTTTTTTACTACGCTGTTGTA-3’ |
| Epo | 5’ -AGTCGGGTTCTGGAGAGTGA-3’ | 5’ -ACTTGTGGTATCTGGAGGGGTA-3’ |
| Erfe | 5’ -ACTCAGAACAGCGCCAAAGAA-3’ | 5’ -TTCTCGAGCCCCACATCAAGT-3’ |
| IL-6 | 5’ -GCTCTTCCAGGAAAGCTATG-3’ | 5’ -ACTGCTGTGTTGTTGGTGT-3’ |

Forward and reverse primers used for PCR analysis of gene expression are listed.

do:10.1371/journal.pone.0161033.t004
### Table 5. Statistical Summary.

| Parameter                  | Fe main effect       | Cu main effect       | Fe x Cu interaction |
|----------------------------|----------------------|----------------------|---------------------|
| Growth rate                | **** p<0.0001        | **** p<0.0001        | *** p = 0.0002      |
| Final body weight          | **** p<0.0001        | ** p = 0.0055        | *** p = 0.0001      |
| Liver/Body weight          | **** p<0.0001        | ns p = 0.2303        | * p = 0.0139        |
| Heart/Body weight          | **** p<0.0001        | **** p<0.0001        | ** p = 0.0011       |
| Spleen/Body weight         | **** p = 0.0002      | ns p = 0.0688        | *** p<0.0001        |
| Kidney/Body weight         | ns p = 0.6499        | ns p = 0.6246        | ns p = 0.2177       |
| Hb                         | **** p<0.0001        | **** p<0.0001        | **** p<0.0001      |
| Hct (%)                    | **** p<0.0001        | **** p<0.0001        | **** p<0.0001      |
| Nonheme serum Fe           | **** p<0.0001        | **** p = 0.0001     | **** p<0.0001      |
| Nonheme liver Fe$^d$       | **** p<0.0001        | ** p = 0.0064        | ** p = 0.0026      |
| Nonheme splenic Fe$^d$     | **** p<0.0001        | ** p = 0.0064        | ** p = 0.0026      |
| TIBC                       | **** p<0.0001        | ns p = 0.1559        | **** p = 0.0007    |
| Tf saturation (%)          | **** p<0.0001        | **** p<0.0001        | **** p<0.0006      |
| Epo (mRNA)$^r$             | **** p<0.0001        | **** p<0.0001        | **** p<0.0001      |
| Epo (protein)$^r$          | **** p<0.0001        | **** p<0.0001        | **** p<0.0001      |
| Hepc (mRNA)$^r$            | **** p<0.0001        | ns p = 0.5728        | **** p = 0.0010    |
| Erfe (mRNA)                | **** p<0.0001        | **** p = 0.0002     | **** p<0.0001      |
| Cp activity                | **** p<0.0001        | **** p<0.0001        | **** p<0.0001      |
| Bone Fe                    | **** p<0.0001        | ns p = 0.6337        | ns p = 0.1918      |
| Enterocyte Fe              | **** p = 0.0003      | ns p = 0.2844        | ns p = 0.4764      |
| Liver Fe$^d$               | **** p<0.0001        | ns p = 0.6249        | ** p = 0.0017      |
| Heart Fe                   | ns p = 0.1825        | ns p = 0.7213        | ns p = 0.0934      |
| Kidney Fe                  | **** p<0.0001        | ** p = 0.0068        | ** p = 0.0040      |
| Serum Fe                   | **** p<0.0001        | ns p = 0.3135        | *** p = 0.0002     |
| Bone Cu                    | ** p = 0.0019        | **** p<0.0001        | ns p = 0.5927      |
| Enterocyte Cu              | ns p = 0.0884        | **** p<0.0001        | ** p = 0.0019      |
| Liver Cu                   | **** p<0.0001        | **** p<0.0001        | **** p<0.0001      |
| Heart Cu                   | **** p<0.0001        | **** p<0.0001        | **** p<0.0001      |
| Kidney Cu                  | **** p = 0.0001      | **** p<0.0001        | ns p = 0.1579      |
| Serum Cu                   | * p = 0.0445         | **** p<0.0001        | ** p = 0.0016      |
| Est. av. calorie intake    | * p = 0.0163         | ns p = 0.0734        | ns p = 0.5834      |

ns = not significant

* p<0.005
** p<0.001
*** p<0.0005
**** p<0.0001

* Statistical analysis performed from log10 transformed data.

doi:10.1371/journal.pone.0161033.t005

## Results

### Growth Rates and Organ Weights Differed Among Experimental Groups

Rats consuming the LFe diets grew slower than controls (i.e. the AdFe/AdCu group), irrespective of copper content. Unexpectedly, rats fed the HFe diets also showed a significant reduction in growth rate and final body weight, but increasing copper content (from low to high).
progressively restored these parameters (Fig 1A and 1B). Alterations in growth were probably not the result of changes in energy intake as the amount of food provided to the different experimental groups was similar (Table 6). Moreover, liver weights were generally lower in the

![Fig 1. High-iron feeding impaired growth and caused cardiac hypertrophy.](image)

Table 6. Estimated Average Daily Calorie Intake.

| Dietary Gro | LFe/LCu       | LFe/AdCu     | LFe/HCu   | AdFe/LCu     | AdFe/AdCu | AdFe/HCu | HFe/LCu | HFe/AdCu | HFe/HCu |
|-------------|---------------|--------------|-----------|--------------|-----------|----------|---------|----------|---------|
| kcal/rat/d  | 25.6 ± 2.11*  | 24.6 ± 2.83 (6) | 25.4 ± 1.33 (6) | 25.6 ± 1.40 (6) | 25.6 ± 2.91 (6) | 28.7 ± 1.47 (6) | 23.3 ± 0.86 (6) | 23.7 ± 1.58 (6) | 26.4 ± 2.04 (6) |

* Values are means ± SDs.

Numbers in parentheses indicate n values.

doi:10.1371/journal.pone.0161033.t006
LFe groups, while consumption of the HFe/HCu diet increased liver weights (as compared to all AdFe and the HFe/LCu groups) (Fig 1C). Heart weights were higher in the LFe/LCu, HFe/LCu and HFe/Ad Cu groups (Fig 1D); adding extra copper to these diets, however, prevented cardiac hypertrophy. Spleens were larger only in rats consuming the LFe/LCu diet, while kidney weights did not vary significantly among groups (Table 7). In sum, these data suggest that high-iron feeding impairs copper homeostasis, given that cardiac hypertrophy is a hallmark of severe copper deficiency and that this was prevented by higher copper intake. Further supporting this possibility are the noted anemia and growth impairment (in the absence of iron deficiency), which also typify copper deprivation.

Low- and High-Iron Consumption Altered Hematological Parameters

Hb levels were depressed in rats consuming the LFe diets with copper content not having any affect (Fig 2A). Hb levels were also lower in rats fed the HFe/LCu and HFe/AdCu diets, but consumption of the HFe/HCu diet prevented deficits in Hb. A similar trend was noted in Hct levels (Fig 2B). Moreover, nonheme serum iron was low in the LFe groups, while HFe feeding did not alter this parameter except for in the HFe/HCu group, in which it was significantly increased (Fig 2C). Tf saturation was also depressed in the LFe groups, and values were increased significantly in the HFe/AdCu and HFe/HCu groups (Fig 2D). Furthermore, TIBC trended higher in the LFe groups (Fig 2E). These observations further support the postulate that high-iron feeding perturbs copper homeostasis, since copper deficiency causes an iron deficiency-like anemia. Prevention of the anemia by increasing the copper content of the HFe diet is also congruent with this supposition.

Renal Epo Expression Was Induced by Copper Deprivation in Iron-Deficient and Iron-Loaded Rats

Since hematological parameters were altered, unexpectedly, in rats consuming the HFe diets, we next assessed levels of the erythroid hormone, erythropoietin (Epo). Renal Epo mRNA expression and serum Epo protein levels were significantly increased in rats consuming the LFe/LCu and HFe/LCu diets (Fig 3A and 3B). Moreover, a strong correlation between renal Epo mRNA and serum Epo protein levels was noted (Fig 3B, inset). Increased Epo levels only in rats consuming the LFe/LCu and HFe/LCu diets suggests that copper deprivation increases Epo expression, independent of hypoxia or anemia, since some anemic, presumably hypoxic, rats (e.g. in the LFe/AdCu, LFe/HCu and HFe/AdCu groups) did not show such dramatic increases in Epo expression.

The Erythroid Iron Regulator, Erfe, Was Induced by Copper Deprivation in the Spleens of Iron-Deficient Rats

Recently, an erythropoietic stress-related hormone, erythroferrone ([Erfe]) [22], was discovered. Erfe is expressed in developing erythrocytes and spleen (which is an erythropoietic organ

Table 7. Relative Spleen and Kidney Weights.

| % of BW | LFe/LCu | LFe/AdCu | LFe/HCu | AdFe/LCu | AdFe/AdCu | AdFe/HCu | HFe/LCu | HFe/AdCu | HFe/HCu |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Spleen  | 0.52 ± 0.06** (8) | 0.32 ± 0.03* (6) | 0.34 ± 0.04* (6) | 0.28 ± 0.05* (6) | 0.33 ± 0.02* (6) | 0.36 ± 0.06* (6) | 0.31 ± 0.12* (6) | 0.33 ± 0.06* (6) | 0.39 ± 0.11* (6) |
| Kidney  | 0.51 ± 0.10 (8) | 0.46 ± 0.02 (6) | 0.45 ± 0.05 (6) | 0.43 ± 0.04 (6) | 0.44 ± 0.04 (6) | 0.48 ± 0.05 (6) | 0.51 ± 0.10 (6) | 0.51 ± 0.04 (6) | 0.50 ± 0.04 (6) |

* Values are means ± SDs. Labeled means without a common letter differ, p<0.05 (2-factor ANOVA).
* Numbers in parentheses indicate n values.
Erfe was reported to be induced by circulating Epo and it functions to suppress hepatic Hamp (the gene encoding hepcidin [Hepc]) expression. Given that serum Epo protein levels increased in some of our experimental rats, we next assessed splenic Erfe mRNA levels. 

**Fig 2. Consumption of the low- and high-iron diets altered hematological parameters.** Hemoglobin (Hb) (A) and hematocrit (Hct) (B) were determined from whole blood collected from experimental animals at sacrifice. Serum nonheme iron (C), serum transferrin saturation (D) and total iron-binding capacity (TIBC) (E) were also quantified. Labeled means without a common letter differ \( p < 0.05 \). n values and abbreviations used are the same as in Fig 1. The Box-and-Whisker plots indicate the following: the minimum value (the lower whisker), the lower quartile, the median, the upper quartile and the maximum value (the upper whisker). 2-way ANOVA factor analysis results are as follows: hemoglobin (Fe: \( p < 0.0001 \); Cu: \( p < 0.0001 \); Fe X Cu: \( p < 0.0001 \)); hematocrit (Fe: \( p < 0.0001 \); Cu: \( p < 0.0001 \); Fe X Cu: \( p < 0.0001 \)); serum nonheme iron (Fe: \( p < 0.0001 \); Cu: \( p < 0.001 \); Fe X Cu: \( p < 0.0001 \)); serum transferrin saturation (Fe: \( p < 0.0001 \); Cu: \( p < 0.0001 \); Fe X Cu: \( p < 0.001 \)) and TIBC (Fe: \( p < 0.0001 \); Cu: ns; Fe X Cu: \( p < 0.001 \)). ns, not significant.

doi:10.1371/journal.pone.0161033.g002
expression. Quantification of mRNA levels is of relevance, since Erfe is regulated at the transcript level by erythropoietic stress [23]. Erfe expression was dramatically increased only in rats consuming the LFe/LCu diet (Fig 3C). Surprisingly, Erfe expression was, however, not increased in the HFe/LCu group, despite significant anemia/hypoxia and strong induction of Epo expression in these animals. Therefore, since Erfe was only induced in anemic rats in the setting of low splenic iron (Fig 3D), we speculate that induction of Erfe expression by Epo may be inhibited by iron accumulation. This would be a logical supposition since suppression of Hepc expression during iron loading would only exacerbate tissue iron accumulation. This is also consistent with the noted suppression of Hepc expression (as described below) in only the low iron-fed rats.

Fig 3. Renal Epo and splenic Erfe levels increased in rats consuming the LFe/LCu diet. Renal Epo mRNA (A) and serum Epo protein levels (B) were assessed in experimental rats. The Pearson product-moment correlation coefficient (r) comparing these 2 parameters is noted in the inset of panel B ($p<0.0001$). Splenic Erfe mRNA expression was quantified by qRT-PCR (C) and splenic nonheme iron levels (D) were measured using a commonly used technique. Labeled means without a common letter differ ($p<0.05$). Values are means ± SDs. n values and abbreviations used are the same as in Fig 1. Data for Epo mRNA and protein expression and splenic nonheme iron concentration were log$_{10}$ transformed prior to running statistical analyses due to large variations in values. For ease of interpretation, we have, however, presented the non-transformed data in the figure. 2-way ANOVA factor analysis results are as follows: renal Epo mRNA (Fe: $p<0.0001$; Cu: $p<0.0001$; Fe X Cu: $p<0.0001$); serum Epo protein (Fe: $p<0.0001$; Cu: $p<0.0001$; Fe X Cu: $p<0.0001$); splenic Erfe (Fe: $p<0.0001$; Cu: $p<0.0001$; Fe X Cu: $p<0.0001$); and splenic nonheme iron (Fe: $p<0.0001$; Cu: $p<0.0001$; Fe X Cu: $p<0.01$).

doi:10.1371/journal.pone.0161033.g003
Hepatic Nonheme Iron Loading Increased in the HFe/HCu Group

Hepc is a liver-derived, peptide hormone that is considered the master regulator of iron homeostasis. Given that Hamp expression is controlled predominantly at the level of transcription, we next quantified hepatic Hepc mRNA levels. As expected, Hepc mRNA expression was essentially nil in all rats consuming the LFe diets (Fig 4A). Consumption of the HFe diet increased Hepc mRNA expression, with higher copper content leading to a trend towards a more dramatic increase. Since one driver of Hamp gene expression is serum Tf saturation [24, 25], Pearson’s test was utilized to relate Hepc mRNA expression to Tf saturation. Results showed a strong correlation (Fig 4B). Moreover, hepatic iron levels paralleled changes in Hepc

![Graphical representation of Hepc mRNA expression](image)

**Fig 4.** Extra copper in the HFe diets did not influence Hepc mRNA expression but it accentuated hepatic nonheme iron loading. Hepc mRNA expression was quantified in experimental rats (A), and the relationship between Hepc mRNA expression (log10) and Tf saturation was estimated by calculating Pearson product-moment correlation (B). The line of best fit is shown along with the correlation coefficient (r) (p<0.0001). Hepatic total (C, left side) and nonheme (C, right side) iron was also measured. Note that the 2 halves of panel C are mirror images with respect to the order of the experimental groups. Correlations were also calculated between Hepc mRNA expression (log10) and liver iron levels (log10) (r values are shown as insets) (C). Labeled means without a common letter differ (p<0.05). Values are means ± SDs. n values and abbreviations used are the same as in Fig 1. Data for Hepc mRNA and hepatic total and nonheme iron concentrations were log10 transformed prior to running statistical analysis due to large variations in values. For ease of interpretation, we have, however, presented the non-transformed data in the figure. a.u., arbitrary units. 2-way ANOVA factor analysis results are as follows: Hepc (Fe: p<0.0001; Cu: ns; Fe X Cu: p<0.001); total liver iron (Fe: p<0.0001; Cu: ns; Fe X Cu: p<0.01); and hepatic nonheme iron (Fe: p<0.0001; Cu: p<0.01; Fe X Cu: p<0.01). ns, not significant.

doi:10.1371/journal.pone.0161033.g004
mRNA expression (Fig 4C). The most significant iron loading was noted in rats consuming the HFe diet with extra copper, which coincidently, is the same group that had the highest Hepc expression. There was also a strong correlation between Hepc mRNA levels and hepatic iron stores (total and nonheme) (Fig 4C, insets). Furthermore, given that interleukin 6 (IL-6) and bone morphogenetic protein 6 (Bmp6) are regulators of hepatic Hamp expression, we also quantified the expression of these genes by qRT-PCR; both were generally lower in the LFe groups as compared to the others (data not shown). These data did not correlate with Hepc mRNA levels, however, so their significance is unclear.

**High-Iron Feeding Increased Tissue Iron Levels**

Iron in bone (tibia) was increased in only the HFe groups (Table 8). Iron content of heart did not vary, while kidney iron levels were higher in only the HFe/AdCu and HFe/HCu groups. The iron content of isolated enterocytes [26] was higher in the HFe/LCu group; other differences were apparent, but due to large variation, they did not achieve statistical significance.

**High-Iron Feeding Caused Systemic Copper Deficiency**

Results described above suggested that, predictably, rats consuming the low-iron diets developed iron-deficiency anemia (IDA). What was unexpected, however, was the development of anemia in rats consuming the HFe diets. Since anemia did not occur when the HFe diet contained extra copper, we postulated that decrements in Hb and Hct likely reflected copper-deficiency anemia (CDA). To directly address this possibility, we measured copper content in various tissues and blood as well as circulating levels of Cp, which is an accepted marker of severe copper deficiency [19, 27]. Liver copper content was lowest in the rats consuming the LCu diets, irrespective of iron content (Fig 5A). Hepatic copper content was also similarly diminished in the rats consuming the HFe/AdCu diet, but copper levels were similar to control levels in the HFe/HCu group. Moreover, significant hepatic copper loading occurred in the LFe/HCu group, which is consistent with previous observations that liver copper content increases in iron deficiency [28]. In general, this same pattern was also seen in regards to serum, heart and bone copper content (Fig 5B–5D). Furthermore, serum Cp (i.e. amine oxidase) activity was depressed in all LCu groups, with increasing copper content in the HFe diets leading to increments in Cp activity (Fig 5E). Cp activity correlated with liver copper content (Fig 5F), which supports the previous postulate that hepatic copper loading promotes biosynthesis of the holo (copper-containing) form of the Cp enzyme [10]. Moreover, kidney and enterocyte copper levels showed only minor variations with limited significance (Table 9). Overall, these data further support our postulate that the anemia caused by feeding a high-iron diet to weanling rats is the result of systemic copper deficiency.

**Discussion**

This investigation tested the hypothesis that varying dietary copper intake would influence iron metabolism during disturbances of iron homeostasis. We chose a dietary approach in which groups of weanling rats were fed diets with low, normal or high iron content in combination with low, normal or high copper levels. As the feeding protocol proceeded, we noted that rats consuming the LFe diets grew slower than controls, as was anticipated. Unexpectedly, however, the same phenomenon was observed in the HFe groups, but decrements in growth were more severe. A reasonable postulate was that growth was impaired as a result of iron toxicity; however, final body weights of rats fed the high-iron diet with extra copper were not different from controls, suggesting that copper depletion was the underlying reason for growth deficits. It was also puzzling that impaired growth was not associated with reduced food
Table 8. Tissue Iron Levels.

| μg/g | LFe/LCu | LFe/AdCu | LFe/HCu | AdFe/LCu | AdFe/AdCu | AdFe/HCu | HFe/LCu | HFe/AdCu | HFe/HCu |
|------|---------|----------|---------|----------|-----------|-----------|---------|----------|---------|
| Serum | 3.62 ± 2.97** (8) | 5.29 ± 2.31* (5) | 7.22 ± 6.66* (6) | 24.05 ± 15.37* (5) | 14.14 ± 7.29* (6) | 8.17 ± 2.52* (6) | 10.94 ± 6.39* (4) | 10.81 ± 4.86* (5) | 25.16 ± 6.78* (6) |
| Heart | 905 ± 226 (9) | 745 ± 437 (6) | 610 ± 66 (6) | 1282 ± 897 (6) | 860 ± 209 (6) | 920 ± 365 (6) | 620 ± 85 (6) | 918 ± 436 (6) | 1037 ± 503 (6) |
| Kidney | 357 ± 140* (9) | 368 ± 194* (6) | 260 ± 80* (5) | 403 ± 125* (6) | 586 ± 269** (6) | 382 ± 47** (6) | 440 ± 197** (6) | 1065 ± 647** (6) | 1125 ± 201** (6) |
| IECs | 124 ± 73 (9) | 94 ± 46 (6) | 44 ± 48 (6) | 113 ± 52 (6) | 132 ± 140 (6) | 143 ± 118 (6) | 817 ± 926 (6) | 438 ± 348 (6) | 377 ± 350 (6) |
| Bone | 35 ± 15 (7) | 24 ± 5.4 (4) | 48 ± 38 (4) | 53 ± 15 (4) | 71 ± 15 (4) | 54 ± 21 (4) | 158 ± 32 (4) | 168 ± 50 (4) | 129 ± 17 (4) |

* Values are means ± SDs. Labeled means without a common letter differ, p<0.05 (2-factor ANOVA).
** Numbers in parentheses indicate n values.
† Intestinal epithelial cells isolated from duodenum

doi:10.1371/journal.pone.0161033.t008
Fig 5. High-iron feeding resulted in severe tissue copper depletion and reduced Cp activity. The copper concentration in liver (A), serum (B), heart (C) and bone (D) was determined by ICP-MS. Cp (i.e. amine oxidase) activity was also measured in serum samples (E). The correlation between Cp activity and liver copper concentrations (log10) was calculated using Pearson product-moment correlation analysis (F). The line of best fit is shown along with the correlation coefficient (r) (p<0.0001). Labeled means without a common letter differ (p<0.05). n values and abbreviations used are the same as in Fig 1. The Box-and-Whisker plots indicate the following: the minimum value (the lower whisker), the lower quartile, the median, the upper quartile and the maximum value (the upper whisker). 2-way ANOVA factor analysis results are as follows: liver copper (Fe: p<0.0001; Cu: p<0.0001; Fe X Cu: p<0.0001); serum copper (Fe: p<0.05; Cu: p<0.0001; Fe X Cu: p<0.01); heart copper (Fe: p<0.0001; Cu: p<0.0001; Fe X Cu: p<0.0001); bone copper (Fe: p<0.01; Cu: p<0.0001; Fe X Cu: ns); and Cp activity (Fe: p<0.0001; Cu: p<0.0001; Fe X Cu: p<0.0001).
consumption. However, considering the critical role of copper in energy metabolism, as a participant in electron transfer reactions in mitochondria (e.g. in cytochrome C oxidase), it was a logical postulate that impaired nutrient utilization (i.e. ATP synthesis) underlies growth defects. Growth deficits associated with copper deficiency have been reported previously [29, 30]. Other physiologic perturbations that were observed in rats consuming the HFe diets included: 1) cardiac hypertrophy, consistent with severe copper deficiency [31]; 2) anemia in the presence of adequate (or elevated) iron stores and normal serum nonheme iron levels; 3) robust induction of Epo in iron-replete animals; and 4) decreased tissue copper levels and reduced serum Cp activity. The fact that adding extra copper to the HFe diets prevented these physiologic perturbations proved that they were the consequence of copper depletion. High-iron feeding of rapidly growing rats thus causes CDA. Precedence for such mineral interactions has been established, as, for example, high zinc intake induces severe copper deficiency in humans [32, 33].

Our experimental findings support an earlier study which demonstrated that higher iron intake was associated with increased dietary copper requirements [34]. Moreover, previous investigations have provided evidence that iron, when in excess, can antagonize copper metabolism [35]. The mechanism by which high-iron feeding perturbs copper homeostasis occurs is unknown. One seemingly likely possibility is that high iron levels in the intestinal lumen impair copper absorption. To test this postulate, however, would require additional experimentation which is beyond the scope of the current investigation.

Other investigators have measured growth and Hb levels in rodents fed high-iron diets [36–38], including some studies that have used weaning SD rats [39, 40]. In general, most studies documented decrements in body weight after high-iron feeding. A mechanistic explanation for altered growth rates was, however, not provided. A few studies also measured Hb levels after high-iron feeding and showed no changes [36, 40] or an increase [39]. Differences between these previous studies and the current investigation could relate to the diets used, the length of feeding, the specific strain of mouse or rat used, and/or to rodent housing conditions.

In addition to the observation that high-iron feeding perturbs copper homeostasis, other notable findings have resulted from this investigation, all further supporting the concept that copper influences iron homeostasis. Although, in most cases, we cannot provide mechanistic explanations for these observations, they are nonetheless of potential physiologic significance. One interesting observation was that increasing the copper content of the HFe diets led to incremental increases in liver weights, with the HFe/HCu group having the largest livers (by mass) of all experimental groups. Hepatic Hepc expression and liver iron levels showed a similar pattern, with the highest Hepc mRNA expression and the greatest quantity of hepatic total and nonheme iron in the HFe/HCu group. Copper levels were normal in the livers of this group of rats. It is thus a plausible postulate that iron loading induced the noted hepatomegaly. How copper exacerbates liver iron accumulation in this dietary iron-overload model is unclear, but a reciprocal relationship between hepatic iron and copper content has been noted previously [1, 2]. Furthermore, higher copper in the high-iron diet caused an increase in nonheme serum iron (above the other HFe groups). This is consistent with increases in Tf saturation in

| Table 9. Tissue Copper Levels. |
|-----------------------------|
| μg/g | LFe/LCu | LFe/AdCu | LFe/HCu | AdFe/LCu | AdFe/AdCu | AdFe/HCu | HFe/LCu | HFe/AdCu | HFe/HCu |
| Kidney | 29.6 ± 16.1* (9) | 29.5 ± 5.5 (6) | 34.7 ± 2.8 (6) | 20.3 ± 3.1 (6) | 30.5 ± 4.7 (6) | 40.4 ± 9.9 (6) | 12.4 ± 1.1 (6) | 17.3 ± 5.3 (6) | 30.8 ± 2.6 (6) |
| IECs† | 0.60 ± 0.33* (9) | 2.23 ± 2.40* (6) | 1.34 ± 1.08* (5) | 1.08 ± 1.06* (6) | 0.71 ± 0.49* (6) | 6.69 ± 4.33* (6) | 1.01 ± 0.87* (6) | 0.90 ± 1.55* (6) | 4.16 ± 1.91* (6) |

* Values are means ± SDs. Labeled means without a common letter differ, p<0.05 (2-factor ANOVA).
† Numbers in parentheses indicate n values.
‡ Intestinal epithelial cells isolated from duodenum.

doi:10.1371/journal.pone.0161033.t009
rats consuming the HFe/HCu diet. Conceivably, higher Cp activity in these rats could increase serum iron levels by enhancing iron release from stores into the blood plasma. Moreover, higher copper intake in the iron-overload groups significantly reduced splenic nonheme iron levels. How this might occur is unclear, especially given that tissue and blood copper levels were normal (same as controls) in the HFe/HCu group.

We further noted that renal Epo mRNA expression and serum Epo protein levels were increased only in rats consuming the LFe/LCu and HFe/LCu diets. Given that Epo expression is induced by hypoxia (HIF signaling) [41, 42], it was surprising that renal Epo levels were not increased in the LFe/AdCu and LFe/HCu groups, as rats consuming these diets were anemic (and thus also likely hypoxic). The main difference between the anemic/hypoxic rats that showed robust Epo expression and those that showed lesser or no induction was thus dietary copper deprivation. Since copper deficiency causes anemia, it is a logical postulate that copper deprivation can induce Epo expression; we did indeed find one published report showing a similar phenomenon [43]. It thus appears that CDA is a stronger driver of renal Epo expression than iron deprivation. Elucidating the mechanism by which this occurs is an experimental imperative for future investigation.

Another notable observation deriving from this investigation relates to hepatic Hepc mRNA expression. The Hamp gene is trans-activated when body iron stores increase. One mechanism by which this occurs relates to competition between transferrin receptors expressed in hepatocytes (TfR1 and TfR2) [44, 45]. When serum Tf saturation levels are high, TfR2 outcompetes TfR1 for available dfferic Tf, thus inducing an intracellular signaling cascade that increases Hamp gene transcription. In our investigation, we noted that high-iron feeding led to induction of Hepc mRNA levels, as anticipated. What was unexpected, however, was that higher copper intake further increased Hepc mRNA levels in some iron-loaded rats, suggesting that copper may influence Hamp expression.

When body iron stores are low and erythropoietic demand increases (due to anemia/hypoxia), the Hamp gene is effectively silenced. A recently discovered peptide hormone, called erythroferrone (Erfe) [22], produced and secreted by developing erythrocytes and the spleen, has been proposed as an erythroid regulator of iron homeostasis. It was further suggested that Epo induces Erfe expression, and that Erfe then downregulates hepatic Hamp expression, thus allowing robust intestinal iron absorption and iron release from stores. Since Erfe transcript levels increase in response to erythropoietic stress, we quantified Erfe mRNA expression levels in the spleens of our experimental rats. As described above, we noted robust Epo expression in only 2 groups of rats, those consuming the LFe/LCu and the HFe/LCu diets. We thus expected that Erfe expression would be increased in these groups. This prediction was correct in regards to the rats consuming the LFe/LCu diets, but conversely, Erfe expression was very low in the rats consuming the HFe/LCu diet. This is consistent with hepatic Hepc mRNA levels in these groups (i.e. low in the LFe/LCu group and much higher in the HFe/LCu group), since Erfe is proposed to downregulate Hamp expression. To understand why Erfe would be differentially expressed in these dietary groups, in spite of significant anemia and robust Epo expression in both, it is necessary to identify differences in the pathological phenotypes. Further, since Erfe transcript levels did not increase in response to circulating Epo in the HFe/LCu group, it is logical to consider changes in the spleen. Notably, splenic nonheme iron was low in the LFe/LCu group but >45 times higher in the HFe/LCu group. It could thus be that high splenic iron inhibits Epo-induced Erfe expression. The physiologic signals associated with high systemic iron in the HFe/LCu group may trump the anemia (which relates to low copper in these rats), so Erfe expression remains low and Hepc expression remains high.

In summary, this investigation has revealed heretofore unrecognized interactions between the essential trace minerals iron and copper. High-iron feeding with low or adequate copper levels was shown to induce CDA in growing rats. Although the mechanism by which copper
deficiency causes anemia is unknown, it likely relates to an unidentified copper-dependent step in mitochondrial heme synthesis in developing erythrocytes [2]. The phenotype of CDA in rats may be more severe than that associated with IDA, as exemplified by the more significant growth retardation seen in the copper-deprived rats (but iron toxicity may have also contributed). Adding extra copper to the HFe diet prevented the development of CDA, essentially proving that the noted physiologic perturbations directly related to copper. These findings raise the question of whether iron supplementation in humans could, over the long term, induce deficiencies in copper, as has been proposed before [34, 35]. Although this investigation used a very high level of iron, there are examples of humans who, for medical reasons, consume large quantities of iron. For example, patients with chronic kidney disease are often treated with phosphate binders [46], since hyperphosphatemia is common in this condition [47]. One such phosphate binder is ferric citrate [48, 49]. Patients with end-stage disease (stage 4 or 5) may thus receive 0.21 grams of iron up to 3 times per day (as ferric citrate) for long periods of time [50]. This is up to >35 times more iron than the typical human consumes from a normal varied diet (average ~18 mg/day). Other groups which are likely to require iron supplementation are pregnant women, women of childbearing age, those chronically consuming proton-pump inhibitors for gastric acid reflux, and those suffering from malabsorptive disorders (e.g. Crohn’s disease, colitis) or after gastric bypass surgery. An interesting question relates to whether extra copper should be added to iron supplements to avoid any untoward effects of high iron intake on copper homeostasis. This concept was proposed earlier [34] and the current work provides additional support for this contention. Interestingly, iron supplements containing extra copper were promoted for the anemia of pregnancy in the 1930s, but their use seems to have ended sometime shortly thereafter [35]. One future goal is to define the minimum amount of dietary iron that is required to induce copper deficiency in rats, so as to be able to better extrapolate results to humans who consume iron supplements.

Acknowledgments

We thank Dr. Mitchell Knutson, University of Florida, for helpful discussions related to interpreting the data from this investigation. We also thank Dr. Joseph Prohaska, University of Minnesota, Duluth, for helpful discussions regarding experimental design.

Author Contributions

**Conceptualization:** JFC JHH.

**Formal analysis:** JHH.

**Funding acquisition:** JFC.

**Investigation:** JHH CG XW SRF.

**Methodology:** JFC JHH CG XW SRF.

**Project administration:** JFC.

**Supervision:** JFC.

**Validation:** JHH JFC.

**Visualization:** JHH.

**Writing - original draft:** JHH JFC.

**Writing - review & editing:** JFC JHH CG SRF XW.
References

1. Gulec S, Collins JF. Molecular mediators governing iron-copper interactions. Annu Rev Nutr. 2014; 34:95–116. doi: 10.1146/annurev-nutr-071812-161215 PMID: 24995690; PubMed Central PMCID: PMCPMC4316823.

2. Fox PL. The copper-iron chronicles: the story of an intimate relationship. Biometals. 2003; 16(1):9–40. PMID: 12572662.

3. Ravia JJ, Stephen RM, Ghishan FK, Collins JF. Menkes Copper ATPase (Atp7a) is a novel metal-responsive gene in rat duodenum, and immunoreactive protein is present on brush-border and basolateral membrane domains. J Biol Chem. 2005; 280(43):36221–7. doi: 10.1074/jbc.M506727200 PMID: 16081413; PubMed Central PMCID: PMCPMC1350954.

4. Collins JF, Franck CA, Kowdley KV, Ghishan FK. Identification of differentially expressed genes in response to dietary iron deprivation in rat duodenum. Am J Physiol Gastrointest Liver Physiol. 2005; 288(5):G964–71. doi: 10.1152/ajpgi.00489.2004 PMID: 16081413; PubMed Central PMCID: PMCPMC1350954.

5. Collins JF, Hu Z, Ranganathan PN, Feng D, Garrick LM, Garrick MD, et al. Induction of arachidonate 12-lipoxygenase (Alox15) in intestine of iron-deficient rats correlates with the production of biologically active lipid mediators. Am J Physiol Gastrointest Liver Physiol. 2008; 294(4):G948–62. doi: 10.1152/ajpgi.00274.2007 PMID: 18258795.

6. Xie L, Collins JF. Transcriptional regulation of the Menkes copper ATPase (Atp7a) gene by hypoxia-inducible factor (HIF2(alpha)) in intestinal epithelial cells. Am J Physiol Cell Physiol. 2011; 300(6):C1298–305. doi: 10.1152/ajpcell.00023.2011 PMID: 21346155; PubMed Central PMCID: PMCPMC3118616.

7. Xie L, Collins JF. Transcription factors Sp1 and Hif2alpha mediate induction of the copper-transporting ATPase (Atp7a) gene in intestinal epithelial cells during hypoxia. J Biol Chem. 2013; 288(33):23943–52. doi: 10.1074/jbc.M113.489500 PMID: 23814049; PubMed Central PMCID: PMCPMC3745340.

8. Jiang L, Garrick MD, Garrick LM, Zhao L, Collins JF. Divalent metal transporter 1 (Dmt1) mediates copper transport in the duodenum of iron-deficient rats and when overexpressed in iron-deprived HEK-293 cells. J Nutr. 2013; 143(12):1927–33. doi: 10.3945/jn.113.181867 PMID: 24089420; PubMed Central PMCID: PMCPMC3827639.

9. Collins JF, Hu Z, Ranganathan PN, Feng D, Garrick LM, Garrick MD, et al. Induction of arachidonate 12-lipoxygenase (Alox15) in intestine of iron-deficient rats correlates with the production of biologically active lipid mediators. Am J Physiol Gastrointest Liver Physiol. 2008; 294(4):G948–62. doi: 10.1152/ajpgi.00274.2007 PMID: 18258795.

10. Ranganathan PN, Lu Y, Jiang L, Kim C, Collins JF. Serum ceruloplasmin protein expression and activity increases in iron-deficient rats and is further enhanced by higher dietary copper intake. Blood. 2011; 118(11):3146–53. PMID: 21768302.

11. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993; 123(11):1939–51. PMID: 8229312.

12. Reeves PG, Rossow KL, Lindlauf J. Development and testing of the AIN-93 purified diets for rodents: results on growth, kidney calcification and bone mineralization in rats and mice. J Nutr. 1993; 123(11):1923–31. PMID: 8229309.

13. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest. 1983; 71(3):429–39. PMID: 6826715; PubMed Central PMCID: PMCPMC436890.

14. Park CH, Bacon BR, Brittenham GM, Tavill AS. Pathology of dietary carbonyl iron overload in rats. Lab Invest. 1987; 57(5):555–63. PMID: 3682765.

15. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalised liver samples. S Afr J Med Sci. 1968; 33(1):9–11. PMID: 5676884.

16. Young DS, Hicks JM. Method for the Automatic Determination of Serum Iron. J Clin Pathol. 1965; 18:98–102. PMID: 14247712; PubMed Central PMCID: PMCPMC472839.

17. Ramsay WN. The determination of the total iron-binding capacity of serum. Clin Chim Acta. 1957; 2(3):221–6. PMID: 13461309.

18. Babson AL, Kleinman NM. A source of error in an autoanalyzer determination of serum iron. Clin Chem. 1967; 13(2):163–6. PMID: 6017844.

19. Roesser HP, Lee GR, Nacht S, Cartwright GE. The role of ceruloplasmin in iron metabolism. J Clin Invest. 1970; 49(12):2408–17. doi: 10.1172/JCI106460 PMID: 5480864; PubMed Central PMCID: PMCPMC322742.
20. Sunderman FW, Nomoto S. Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem. 1970; 16(11):903–10. PMID: 5473551.

21. Chomczynski P. Reagents and methods for isolation of purified RNA. Google Patents; 2010.

22. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46(7):678–84. doi: 10.1038/ng.2996 PMID: 24880340; PubMed Central PMCID: PMCPMC4104984.

23. Kautz L, Jung G, Nemeth E, Ganz T. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014; 124(16):2569–74. doi: 10.1182/blood-2014-06-584607 PMID: 25193872; PubMed Central PMCID: PMCPMC4199559.

24. Gehrke SG, Kulaksiz H, Herrmann T, Riedel HD, Bents K, Velkamp C, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood. 2003; 102(1):371–6. doi: 10.1182/blood-2002-11-3610 PMID: 12637325.

25. Wilkins SJ, Frazer DM, Millard KN, McLaren GD, Anderson GJ. Iron metabolism in the hemoglobin-deficient mouse: correlation of dfferic transferrin with hepcidin expression. Blood. 2006; 107(4):1659–64. doi: 10.1182/blood-2005-07-2614 PMID: 16239432; PubMed Central PMCID: PMCPMC1895407.

26. Ranganathan PN, Lu Y, Fuqua BK, Collins JF. Immunoreactive hephaestin and ferroxidase activity are present in the cytosolic fraction of rat enterocytes. Biometals. 2012; 25(4):687–95. doi: 10.1007/s10534-012-9527-9 PMID: 22350470; PubMed Central PMCID: PMCPMC3663079.

27. Linder MC, Houle PA, Isaacs E, Moor JR, Scott LE. Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme. 1979; 24(1):23–35. PMID: 436807.

28. Sherman AR, Tissue NT. Tissue iron, copper and zinc levels in offspring of iron-sufficient and iron-deficient rats. J Nutr. 1981; 111(2):266–75. PMID: 7463170.

29. Fields M, Lewis CG, Lure MD, Burns WA. Dietary ferric vs. ferrous iron in copper-deficient rats fed fructose-based diets. J Am Coll Nutr. 1995; 14(4):399–403. PMID: 8568119.

30. Cohen NL, Keen CL, Hurley LS, Lonnerdal B. Determinants of copper-deficiency anemia in rats. J Nutr. 1985; 115(6):710–25. PMID: 3998865.

31. Prohaska JR, Heller LJ. Mechanical properties of the copper-deficient rat heart. J Nutr. 1982; 112 (11):2142–50. PMID: 6215471.

32. Merza H, Sood N, Sood R. Idiopathic hyperzincemia with associated copper deficiency anemia: a diagnostic dilemma. Clin Case Rep. 2015; 3(10):819–22. doi: 10.1002/ccr3.344 PMID: 26509015.

33. Prasad R, Hawthorne B, Durai D, McDowell I. Zinc in denture adhesive: a rare cause of copper deficiency in a patient on home parenteral nutrition. BMJ Case Rep. 2015; 2015. doi: 10.1136/bcr-2015-211390 PMID: 26452740.

34. Kleve LM. Iron overload can induce mild copper deficiency. J Trace Elem Med Biol. 2001; 14(4):237–40. doi: 10.1016/S0946-672X(01)80009-2 PMID: 11396784.

35. Kleve LM. IHD from copper deficiency: a unified theory. Nutr Res Rev. 2016; 1–8. doi: 10.1017/S095442241500010X PMID: 27350652.

36. Yu F, Hao S, Yang B, Zhao Y, Zhang R, Zhang W, et al. Insulin resistance due to dietary iron overload disrupts inner hair cell ribbon synapse plasticity in male mice. Neurosci Lett. 2015; 597:183–8. doi: 10.1016/j.neulet.2015.04.049 PMID: 25956034.

37. Dongiovanni P, Ruscica M, Rametta R, Recalcati S, Stefani L, Gatti S, et al. Dietary iron overload induces visceral adipose tissue insulin resistance. Am J Pathol. 2013; 182(6):2254–63. doi: 10.1016/j.ajpath.2013.02.019 PMID: 23578384.

38. Mackinnon M, Clayton C, Plummer J, Ahern M, Cmielewski P, Ilsley A, et al. Iron overload facilitates hepatic fibrosis in the rat alcohol/low-dose carbon tetrachloride model. Hepatology. 1995; 21(4):1083–8. PMID: 7705783.

39. Nam H, Knutson MD. Effect of dietary iron deficiency and overload on the expression of ZIP metal-ion transporters in rat liver. Biometals. 2012; 25(1):115–24. doi: 10.1007/s10534-011-9487-5 PMID: 21826400; PubMed Central PMCID: PMCPMC4598638.

40. Coffey R, Nam H, Knutson MD. Microarray analysis of rat pancreas reveals altered expression of Alox15 and regulating islet-derived genes in response to iron deficiency and overload. PLoS One. 2014; 9(1):e86019. doi: 10.1371/journal.pone.0086019 PMID: 24465846; PubMed Central PMCID: PMCPMC3897611.

41. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992; 12(12):5447–54. PMID: 1448077; PubMed Central PMCID: PMCPMC360482.
42. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993; 82(12):3610–5. PMID: 8260699.

43. Matak P, Zumerle S, Mastrogiannaki M, El Balkhi S, Delga S, Mathieu JR, et al. Copper deficiency leads to anemia, duodenal hypoxia, upregulation of HIF-2α and altered expression of iron absorption genes in mice. PLoS One. 2013; 8(3):e59538. doi: 10.1371/journal.pone.0059538 PMID: 23555700; PubMed Central PMCID: PMC3610650.

44. Wallace DF, Summerville L, Lusby PE, Subramaniam VN. First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut. 2005; 54(7):980–6. doi: 10.1136/gut.2004.062018 PMID: 15951546; PubMed Central PMCID: PMCPMC1774629.

45. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab. 2009; 9(3):217–27. doi: 10.1016/j.cmet.2009.01.010 PMID: 19254567; PubMed Central PMCID: PMCPMC2673483.

46. Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol. 2016. doi: 10.1007/s40620-016-0266-9 PMID: 26800972.

47. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis. 1992; 19(4):303–17. PMID: 1562018.

48. Matsuo A, Iida A, Tanimoto M, Matsushita M, Miyamoto K. The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats. Ren Fail. 2014; 36 (8):1291–7. doi: 10.3109/0886022X.2014.930491 PMID: 24975675.

49. Pai AB, Jang SM, Wegrzyn N. Iron-based phosphate binders—a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol. 2016; 12(1):115–27. doi: 10.1517/17425255.2016.1110573 PMID: 26572591.

50. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, et al. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis. 2015; 66(3):479–88. doi: 10.1053/j.ajkd.2015.03.013 PMID: 25958079.